(Q40633103)

22 September 2017

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis (English)

1 reference

World Health Organization

22 September 2017

0 references

multiple drug resistance

1 reference

5

1 reference

Giovanni Battista Migliori

22 September 2017

6

1 reference

22 September 2017

Simon Tiberi

2

0 references

Rosella Centis

object named as

Rosella Centis

4

0 references

author name string

Giovanni Sotgiu

1

1 reference

22 September 2017

Lia D'Ambrosio

3

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 June 2016

1 reference

22 September 2017

1 reference

22 September 2017

387

1 reference

22 September 2017

10037

1 reference

22 September 2017

2486-2487

1 reference

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Classification of antituberculosis drugs: a new proposal based on the most recent evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930729-2

7 January 2021

10.1016/S0140-6736(16)30729-2

Identifiers

DOI

1 reference

22 September 2017

1 reference